CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
28.52
0.49%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Arrowhead Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 28.66
Open* 28.4
1-Year Change* 16.39%
Day's Range* 28.13 - 28.96
52 wk Range 20.67-42.48
Average Volume (10 days) 2.54M
Average Volume (3 months) 31.66M
Market Cap 4.08B
P/E Ratio -100.00K
Shares Outstanding 123.10M
Revenue 240.74M
EPS -1.92
Dividend (Yield %) N/A
Beta 0.77
Next Earnings Date Feb 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 28.52 -0.01 -0.04% 28.53 29.02 27.98
Mar 27, 2024 28.66 0.87 3.13% 27.79 28.77 27.79
Mar 26, 2024 27.77 -0.26 -0.93% 28.03 28.40 27.45
Mar 25, 2024 27.83 0.68 2.50% 27.15 27.88 27.10
Mar 22, 2024 27.13 -0.90 -3.21% 28.03 28.27 27.12
Mar 21, 2024 28.16 -0.42 -1.47% 28.58 29.73 28.05
Mar 20, 2024 28.11 0.73 2.67% 27.38 28.31 27.00
Mar 19, 2024 27.69 -0.19 -0.68% 27.88 28.28 27.48
Mar 18, 2024 28.05 0.02 0.07% 28.03 28.29 27.12
Mar 15, 2024 28.23 1.23 4.56% 27.00 28.94 26.95
Mar 14, 2024 27.37 -0.48 -1.72% 27.85 28.17 26.95
Mar 13, 2024 28.53 0.08 0.28% 28.45 29.06 28.10
Mar 12, 2024 28.48 -0.58 -2.00% 29.06 29.27 28.17
Mar 11, 2024 29.33 -3.43 -10.47% 32.76 32.76 29.18
Mar 8, 2024 33.40 -0.18 -0.54% 33.58 35.41 33.32
Mar 7, 2024 33.13 -2.27 -6.41% 35.40 35.72 33.07
Mar 6, 2024 35.35 1.28 3.76% 34.07 35.58 34.07
Mar 5, 2024 34.00 -0.55 -1.59% 34.55 35.36 33.67
Mar 4, 2024 35.04 -1.49 -4.08% 36.53 36.60 34.65
Mar 1, 2024 36.00 3.72 11.52% 32.28 36.17 32.20

Arrowhead Pharma Events

Time (UTC) Country Event
Tuesday, April 30, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Arrowhead Pharmaceuticals Inc Earnings Release
Q2 2024 Arrowhead Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 243.231 138.287 87.9921 168.796 16.1423
Revenue 243.231 138.287 87.9921 168.796 16.1423
Total Operating Expense 421.738 287.323 181.151 107.605 72.0786
Selling/General/Admin. Expenses, Total 130.095 80.08 51.6649 26.5563 19.1101
Research & Development 281.222 198.977 123.543 81.0487 52.9685
Depreciation / Amortization 10.421 8.266 5.943
Unusual Expense (Income) 0
Other Operating Expenses, Total 0
Operating Income -178.507 -149.036 -93.1588 61.1906 -55.9362
Interest Income (Expense), Net Non-Operating 5.033 6.12 9.1905 6.95777 1.48066
Gain (Loss) on Sale of Assets
Other, Net 0.765 2.07 -0.58252 0 0.00749
Net Income Before Taxes -172.709 -140.846 -84.5508 68.1484 -54.4481
Net Income After Taxes -176.494 -140.848 -84.5532 67.9749 -54.4505
Minority Interest 0.431
Net Income Before Extra. Items -176.063 -140.848 -84.5532 67.9749 -54.4505
Net Income -176.063 -140.848 -84.5532 67.9749 -54.4505
Income Available to Common Excl. Extra. Items -176.063 -140.848 -84.5532 67.9749 -54.4505
Income Available to Common Incl. Extra. Items -176.063 -140.848 -84.5532 67.9749 -54.4505
Diluted Net Income -176.063 -140.848 -84.5532 67.9749 -54.4505
Diluted Weighted Average Shares 105.426 103.745 100.722 98.6078 83.6385
Diluted EPS Excluding Extraordinary Items -1.67001 -1.35764 -0.83947 0.68935 -0.65102
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.67001 -1.35764 -0.83947 0.68935 -0.65102
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 15.825 146.267 62.546 31.575 32.412
Revenue 15.825 146.267 62.546 31.575 32.412
Total Operating Expense 118.528 98.102 104.68 115.405 105.321
Selling/General/Admin. Expenses, Total 26.69 25.159 22.651 31.624 32.738
Research & Development 88.563 70.273 79.34 81.121 69.98
Depreciation / Amortization 3.275 2.67 2.689 2.66 2.603
Operating Income -102.703 48.165 -42.134 -83.83 -72.909
Interest Income (Expense), Net Non-Operating -0.986 -0.497 -0.167 1.583 1.24
Other, Net 0.306 0.008 0.507 0.09 -0.377
Net Income Before Taxes -103.383 47.676 -41.794 -82.157 -72.046
Net Income After Taxes -104.125 47.676 -41.811 -85.942 -72.046
Net Income Before Extra. Items -102.946 48.675 -41.325 -85.511 -72.046
Net Income -102.946 48.675 -41.325 -85.511 -72.046
Income Available to Common Excl. Extra. Items -102.946 48.675 -41.325 -85.511 -72.046
Income Available to Common Incl. Extra. Items -102.946 48.675 -41.325 -85.511 -72.046
Diluted Net Income -102.946 48.675 -41.325 -85.511 -72.046
Diluted Weighted Average Shares 107.004 108.143 106.039 105.885 105.753
Diluted EPS Excluding Extraordinary Items -0.96208 0.4501 -0.38972 -0.80758 -0.68127
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.96208 0.4501 -0.38972 -0.80758 -0.68127
Minority Interest 1.179 0.999 0.486 0.431
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 405.299 384.597 322.37 265.247 78.7686
Cash and Short Term Investments 376.396 367.789 315.492 258.704 76.5334
Cash & Equivalents 108.005 184.434 143.583 221.804 30.1332
Short Term Investments 268.391 183.355 171.909 36.8999 46.4002
Total Receivables, Net 1.41 10.255 0.84567 0.66136 0.32738
Accounts Receivable - Trade, Net 1.41 10.255 0.84567 0.66136 0.32738
Prepaid Expenses 7.289 4.362 4.2509 3.318 1.26772
Other Current Assets, Total 20.204 2.191 1.78169 2.56344 0.64012
Total Assets 691.939 710.148 522.504 349.845 111.61
Property/Plant/Equipment, Total - Net 168.588 66.021 47.0179 23.2149 13.9354
Property/Plant/Equipment, Total - Gross 200.142 88.885 63.3224 35.2966 23.7408
Accumulated Depreciation, Total -31.554 -22.864 -16.3044 -12.0816 -9.80536
Intangibles, Net 11.962 13.663 15.3631 17.0636 18.764
Other Long Term Assets, Total 0.218 0.272 0.26536 0.14415 0.14192
Total Current Liabilities 138.85 146.536 40.6814 97.0707 12.365
Accounts Payable 2.868 9.457 6.82891 7.64992 2.8061
Accrued Expenses 61.883 26.024 14.5442 11.4606 8.98069
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.22382
Other Current Liabilities, Total 74.099 111.055 19.3083 77.9601 0.35434
Total Liabilities 293.419 301.326 60.7246 105.254 15.8138
Total Long Term Debt 0 0 0 0 2.1012
Long Term Debt 0 2.1012
Capital Lease Obligations
Minority Interest 19.819 0 -0.55519 -0.55519
Other Liabilities, Total 134.75 154.79 20.0432 8.73851 1.9028
Total Equity 398.52 408.822 461.779 244.591 95.7962
Preferred Stock - Non Redeemable, Net
Common Stock 0.198 0.197 0.19475 0.18788 0.18088
Additional Paid-In Capital 1219.21 1053.39 965.41 664.086 582.903
Retained Earnings (Accumulated Deficit) -820.755 -644.692 -503.844 -419.291 -487.266
Other Equity, Total -0.136 -0.069 0.01843 -0.39162 -0.02156
Total Liabilities & Shareholders’ Equity 691.939 710.148 522.504 349.845 111.61
Total Common Shares Outstanding 105.96 104.327 102.376 95.5063 88.5053
Total Preferred Shares Outstanding
Long Term Investments 105.872 245.595 137.487 44.176
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total Current Assets 470.165 574.81 574.999 405.299 432.388
Cash and Short Term Investments 444.403 481.005 501.831 376.396 416.496
Cash & Equivalents 98.034 134.959 202.249 108.005 139.439
Short Term Investments 346.369 346.046 299.582 268.391 277.057
Total Receivables, Net 1.247 69.434 39.568 1.41 0.239
Accounts Receivable - Trade, Net 1.247 69.434 39.568 1.41 0.239
Prepaid Expenses 10.053 9.935 8.412 7.289 6.761
Other Current Assets, Total 14.462 14.436 25.188 20.204 8.892
Total Assets 795.856 891.308 891.489 691.939 751.782
Property/Plant/Equipment, Total - Net 272.036 226.342 188.969 168.588 140.812
Property/Plant/Equipment, Total - Gross 310.956 262.414 222.804 200.142 170.147
Accumulated Depreciation, Total -38.92 -36.072 -33.835 -31.554 -29.335
Intangibles, Net 10.687 11.112 11.537 11.962 12.387
Long Term Investments 42.758 78.834 115.774 105.872 165.92
Other Long Term Assets, Total 0.21 0.21 0.21 0.218 0.275
Total Current Liabilities 70.227 87.151 122.009 138.85 128.212
Accounts Payable 7.874 9.556 0.796 2.868 5.894
Accrued Expenses 45.448 47.756 54.932 61.883 38.03
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 16.905 29.839 66.281 74.099 84.288
Total Liabilities 431.026 444.536 514.45 293.419 297.855
Total Long Term Debt 263.064 0 0 0 0
Other Liabilities, Total 80.58 339.051 373.108 134.75 149.393
Total Equity 364.83 446.772 377.039 398.52 453.927
Common Stock 0.199 0.199 0.199 0.198 0.198
Additional Paid-In Capital 1281.39 1260.31 1239.18 1219.21 1189.11
Retained Earnings (Accumulated Deficit) -916.351 -813.405 -862.08 -820.755 -735.244
Other Equity, Total -0.411 -0.332 -0.258 -0.136 -0.14
Total Liabilities & Shareholders’ Equity 795.856 891.308 891.489 691.939 751.782
Total Common Shares Outstanding 107.102 106.869 106.14 105.96 105.795
Minority Interest 17.155 18.334 19.333 19.819 20.25
Long Term Debt 263.064
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -176.494 -140.848 -84.5532 67.9749 -54.4505
Cash From Operating Activities -136.131 171.224 -95.3916 173.035 -47.2234
Cash From Operating Activities 10.421 8.267 5.94226 4.43914 4.69928
Non-Cash Items 128.235 76.939 43.9083 13.4624 8.40554
Cash Taxes Paid 0.002 0.002 -0.10344 0.3024 0.0024
Cash Interest Paid 0 0 0 0.02744 0.17338
Changes in Working Capital -98.293 226.866 -60.6889 87.1585 -5.87776
Cash From Investing Activities -5.417 -141.678 -240.778 -47.746 -7.43496
Capital Expenditures -52.777 -23.567 -11.9517 -12.0012 -1.42125
Other Investing Cash Flow Items, Total 47.36 -118.111 -228.826 -35.7448 -6.01371
Cash From Financing Activities 65.186 11.305 257.948 66.382 59.953
Financing Cash Flow Items 60 0 0 -0.05467
Issuance (Retirement) of Stock, Net 5.186 11.305 257.948 68.7971 60.2162
Issuance (Retirement) of Debt, Net 0 -2.41515 -0.20851
Net Change in Cash -76.429 40.851 -78.2215 191.671 5.29465
Foreign Exchange Effects -0.067
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 5.865 -41.811 -176.494 -90.552 -18.506
Cash From Operating Activities -107.187 -75.516 -136.131 -67.464 1.383
Cash From Operating Activities 5.358 2.689 10.421 7.761 5.167
Non-Cash Items 47.826 22.929 128.235 99.465 62.789
Changes in Working Capital -166.236 -59.323 -98.293 -84.138 -48.067
Cash From Investing Activities -116.759 -80.694 -5.417 -41.862 -103.14
Capital Expenditures -66.225 -38.911 -52.777 -20.066 -10.53
Other Investing Cash Flow Items, Total -50.534 -41.783 47.36 -21.796 -92.61
Cash From Financing Activities 251.096 250.576 65.186 64.331 3.731
Issuance (Retirement) of Stock, Net 1.096 0.576 5.186 4.331 3.731
Net Change in Cash 26.954 94.244 -76.429 -44.995 -98.026
Cash Taxes Paid 0 0
Cash Interest Paid 0 0
Financing Cash Flow Items 250 250 60 60
Foreign Exchange Effects -0.196 -0.122 -0.067

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Arrowhead Pharma Company profile

Arrowhead Pharma
Industry: Bio Therapeutic Drugs

177 E Colorado Blvd
Suite 700
PASADENA
CALIFORNIA 91105
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.62 Price
-1.590% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

70,126.15 Price
-0.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading